Update on systemic treatment in early triple negative breast cancer
M. Nunez Abad, Silvia Calabuig‐Fariñas, M. Lobo de Mena, María José Godes Sanz de Bremond, C. García González, Susana Torres‐Martínez, José Ángel García, Vega Iranzo, Carlos Camps Herrero
Abstract
Triple negative breast cancer (TNBC) is a heterogeneous disease representing about 15% of all breast cancers. TNBC are usually high-grade histological tumors, and are generally more aggressive and difficult to treat due to the lack of targeted therapies available, and chemotherapy remains the standard treatment. There is a close relationship between pathological complete response after chemotherapy treatment and higher rates of disease-free survival and overall survival. In this review of systemic treatment in early triple negative breast cancer, our purpose is to analyze and compare different therapies, as well as to highlight the novelties of treatment in this breast cancer subtype.